E Molden
Overview
Explore the profile of E Molden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Novak A, Plaisted H, Hughes Z, Mittermayr A, Molden E
Mar Pollut Bull
. 2023 Nov;
197:115689.
PMID: 37951120
Eelgrass (Zostera marina L.) is a key foundation species that provides multiple ecosystem services to shallow coastal and estuarine systems in the Northern Hemisphere. It is estimated that, over the...
2.
Wollmann B, Syversen S, Lie E, Gjestad C, Mehus L, Olsen I, et al.
Clin Transl Sci
. 2016 Dec;
10(1):42-49.
PMID: 27991741
Systemic inflammation has been linked to suppressed CYP3A(4) activity. We determined 4β-hydroxycholesterol (4βOHC), an endogenous CYP3A4 metabolite, in patients with rheumatoid arthritis (RA) before and after treatment with biological disease-modifying...
3.
Hole K, Gjestad C, Heitmann K, Haslemo T, Molden E, Bremer S
Eur J Clin Pharmacol
. 2016 Dec;
73(3):317-324.
PMID: 27975131
Purpose: Individual variability in the endogenous CYP3A metabolite 4β-hydroxycholesterol (4βOHC) is substantial, but to which extent this is determined by genetic and nongenetic factors remains unclear. The aim of the...
4.
Smith R, Haslemo T, Refsum H, Molden E
Eur J Clin Pharmacol
. 2016 Jun;
72(9):1099-104.
PMID: 27353638
Purpose: Valproic acid (VPA) has an extensive interindividual pharmacokinetic variability. Published data regarding the impact of gender, age, and CYP2C9/2C19 genetics on VPA variability are conflicting, and the purpose of...
5.
Ulvestad M, Skottheim I, Jakobsen G, Bremer S, Molden E, Asberg A, et al.
Clin Pharmacol Ther
. 2013 Jan;
93(3):275-82.
PMID: 23361102
Individual variability in expression and function of organic anion-transporting polypeptide 1B1 (OATP1B1), multidrug resistance protein 1 (MDR1), and/or cytochrome P450 3A4 (CYP3A4) may impact the clinical response of many drugs....
6.
Soderberg M, Haslemo T, Molden E, Dahl M
Pharmacogenomics J
. 2012 Nov;
13(6):544-50.
PMID: 23147717
The widely used antipsychotic drug, olanzapine (OLA) shows large interindividual variability in metabolic clearance. Although the role of the enzymes CYP1A2, CYP2D6 and UGT1A4 has been extensively explored, little is...
7.
Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, et al.
Clin Pharmacol Ther
. 2012 Jun;
92(2):221-7.
PMID: 22713701
Olanzapine, a world leader in antipsychotic drugs, is used in the treatment of schizophrenia and bipolar disorder. There is considerable interpatient variability in its hepatic clearance. Polymorphic glucuronidation of olanzapine...
8.
Rudberg I, Reubsaet J, Hermann M, Refsum H, Molden E
Drug Metab Dispos
. 2009 Sep;
37(12):2340-8.
PMID: 19773541
Systemic exposure of the antidepressant S-citalopram (escitalopram, SCIT) differs several-fold according to variable cytochrome P450 2C19 activity, demonstrating the importance of this enzyme for the metabolic clearance of SCIT in...
9.
Rudberg I, Hermann M, Refsum H, Molden E
Eur J Clin Pharmacol
. 2008 Aug;
64(12):1181-8.
PMID: 18677622
Objective: To investigate the impact of CYP2C19 genotype on serum concentrations of sertraline and N-desmethyl sertraline in psychiatric patients. Methods: Patients treated with sertraline (n = 121) were divided into...
10.
Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E
Clin Pharmacol Ther
. 2007 Jul;
83(2):322-7.
PMID: 17625515
Recently, a novel allelic variant of cytochrome P450 2C19 encoding ultrarapid enzyme activity was described (denoted CYP2C19*17). The objective of this study was to evaluate the impact of CYP2C19*17 on...